Having seized a spot on the 33 list, LunaLEC is Umeå’s latest contribution to the lits of Sweden’s hottest young tech companies.
You are standing there, with a project that needs to be done, but without the time or specific competence needed to follow through. We have an easy and affordable solution: employ a summer entrepreneur.
The eight consecutive Biotech Umeå Investment Day attracted almost 30 Swedish and international investors to Blasierummet at Grand Hotel on the 2 of February 2017 in Stockholm. One of the most appreciated aspects of the event was the flexibility to arrange additional ad-hoc partnering meetings and the size and atmosphere at the event.
In a near future we will be able to detect a concussion by taking a simple blood sample. Several research studies have already confirmed the results and the potential has gained substantial international attention. Behind this new diagnostics technique we find the Umeå based Swedish company, UmanDiagnostics, in collaboration with American Quanterix.
Lipigon is happy to announce 3 new major partners investing in the company. Umeå based Fort Knox Förvaltning AB (Owner of Balticgruppen) and Partnerinvest Övre Norrland AB together with Antaros Medical AB in Gothenburg have entered as new shareholders. The investments allow for Lipigon to expand within present programs and to evaluate novel targets.
Umeå company Betagenon receives €1.8 million, from EU's sought after Horizon 2020 program, to close the gap to the market for their drug against obesity induced diabetes and associated cardiovascular disease. The AMPK activator O304 is the first AMPK activator to reach clinical phase II trials
Asarina Pharma, a drug development company focused on the development of a novel therapy for severe premenstrual symptoms, has completed a financing round raising EURO 7 million from new and existing investors for the continued clinical development of Sepranolone.
Umecrine Cognition AB has announced the closing of a financing round raising SEK 45 million (US$4.9 million) in accordance with the company’s strategy to develop and commercialize its lead compound GR3027 for the treatment of patients with liver cirrhosis and hepatic encephalopathy.
The unique fibrosis model offered by InfiCure is attracting international attention. Last month the startup signed their first contract for a full-service preclinical pilot study to test two substances for an american client in Boston. The trial i currently underway, with all lab work beeing done on location in Umeå.
Clinical trials, intellectual property, and the entrepreneurship in medicine were just a few topics at the panel debate 24 of November. This year’s edition of the national roadshow Bubbel & Debatt took place at Umeå University where around 30 guests joined the panel in discussions on possibilities and hurdlers for innovation and collaboration in the life science field.
Umecrine Cognition announces positive top-line Phase 1 data with GR3027 in hepatic encephalopathy demonstrating safety, tolerability and CNS target engagement
Regulatory for medical devices - Regelverk för medicinteknik
NLS Days 2017
Biotech Umeå, Uminova Innovation
Box 7978, SE-907 19 Umeå